0|10000|Public
30|$|Most of the {{developing}} countries {{do not have a}} homogenous management of venous thrombo-prophylaxis in agreement with international guidelines (Zeitoun <b>et</b> <b>al.</b> 2009; Ouro-Bang’na Maman <b>et</b> <b>al.</b> 2006; Arnaout <b>et</b> <b>al.</b> 2011; Bikdeli and Sharif-Kashani 2012; <b>Mokhtari</b> <b>et</b> <b>al.</b> 2011). For example, the ENDORSE study (Cohen <b>et</b> <b>al.</b> 2008) showed in 2006 that there were still low and heterogeneous rates of appropriate prophylaxis, notably across Latin America, Africa and Middle East countries (from 23  % in Venezuela to 78  % in Tunisia).|$|R
40|$|Copyright © 2014 Sepideh <b>Mokhtari</b> <b>et</b> <b>al.</b> This is an {{open access}} article {{distributed}} under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Sclerosing polycystic adenosis is a rare pathological lesion that affects salivary glands. The majority of cases involve the parotid and its occurrence in minor glands is exceedingly rare. Here, we report the first case of this lesion in the retromolar pad area and discuss its histological features and immunohistochemical reactivity wit...|$|R
30|$|Patients with metastatic {{breast cancer}} often have {{pulmonary}} symptoms with varying aetiologies. Organizing pneumonia mimics infection or progressive malignancy {{and can be}} difficult to diagnose especially in the setting of malignancy. Transtuzumab is a monoclonal antibody against the Her- 2 neu epidermal growth factor receptor, used in the treatment of Her 2 neu over-expressing breast cancers. Only three cases of organising pneumonia, in association with transtuzumab therapy, have previously been described (Travis <b>et</b> <b>al.</b> 2013; King and Mortenson 1992; <b>Mokhtari</b> <b>et</b> <b>al.</b> 2002; Cook-Burns 2001; Vahid and Mehrotra 2006; Perez <b>et</b> <b>al.</b> 2014; Pepels <b>et</b> <b>al.</b> 2009; Romond <b>et</b> <b>al.</b> 2005; Radzikowska <b>et</b> <b>al.</b> 2003; Taus-García <b>et</b> <b>al.</b> 2010; Grudny <b>et</b> <b>al.</b> 2004). We present the report of such a case.|$|R
30|$|Building on {{this theme}} {{of the role of}} calcium in neural processing, <b>Mokhtari</b> <b>et</b> <b>al.</b> (2018) {{investigate}} the information processing properties of a dynamical model of a synapse subject to short-term synaptic plasticity based on calcium-dependent modulation of vesicle release and recovery probabilities [6]. As the model has been validated by data from hippocampal GABAergic synapses [24], it provides a testbed for the effects of muscarine application, which inhibits presynaptic calcium channels, on information transfer in the synapse. By simplifying the presynaptic calcium kinetics, the authors derive a nonlinear map for the calcium concentration, the probability of vesicle release, and the concentration of vesicles in the releasable pool. These vesicle dynamics promote short-term depression which acts as a frequency-dependent filter on Poisson spike trains, as shown in previous work using linear response techniques [25, 26]. <b>Mokhtari</b> <b>et</b> <b>al.</b> (2018) extend these previous findings by analyzing coding using mutual information measures and observe that muscarine application reduces information transfer across input frequencies. The effects of muscarine are modeled by reducing interspike calcium influx to reflect the fact that muscarine binds to acetylcholine receptors and inhibits presynaptic calcium channels. In future work, the authors propose to consider stochastic binding processes using continuous time Markov chain models. In addition, the simple release probability model could be embedded into microcircuit models to understand how short-term plasticity shapes oscillations and rhythms.|$|R
30|$|The use {{of carbon}} paste as an {{electrode}} was initially reported in 1958 by Adams. In afterward researches, {{a wide variety}} of modifiers including enzymes, polymers, and nanomaterials have been used with these versatile electrodes. Carbon paste electrodes (CPEs) are widely applicable in both electrochemical studies and electroanalysis, thanks to their advantages such as very low background current (compared to solid graphite or noble metal electrodes), facility to prepare, low cost, large potential window, simple surface renewal process, and easiness of miniaturization. Besides the advantageous properties and characteristics listed previously, the feasibility of incorporating different substances during paste preparation (which results in the so-called modified carbon paste electrode) allows the fabrication of electrodes with desired composition and, hence, with predetermined properties (Tajik <b>et</b> <b>al.</b> [2013 b]; Khoobi <b>et</b> <b>al.</b> [2013]; <b>Mokhtari</b> <b>et</b> <b>al.</b> [2012]; Díaz <b>et</b> <b>al.</b> [2013]; Gholivand and Mohammadi-Behzad [2014]; Mazloum-Ardakani <b>et</b> <b>al.</b> [2010]; Thomas <b>et</b> <b>al.</b> [2013 a]; Raoof <b>et</b> <b>al.</b> [2007]; Dönmez <b>et</b> <b>al.</b> [2014]; Raoof <b>et</b> <b>al.</b> [2006 a]).|$|R
40|$|Copyright © 2013 Sepideh <b>Mokhtari</b> <b>et</b> <b>al.</b> This is an {{open access}} article {{distributed}} under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Calcifying cystic odontogenic tumor (CCOT) demonstrates considerable diversity in histopathology and clinical behavior. Ghost cell odontogenic carcinoma (GCOC) is the rare malignant counterpart of CCOT and it frequently arises from malignant transformation of a recurrent CCOT. In this paper, we present a case of CCOT and discuss its distinct histopathologic features in recurrence. Then, {{we will have a}} review on clinical, histopathological, and immunohistochemical aspects of GCOC in the literature. Predictive factors of malignant transformation in a benign CCOT will also be discussed. 1...|$|R
40|$|Copyright © 2012 Sepideh <b>Mokhtari</b> <b>et</b> <b>al.</b> This is an {{open access}} article {{distributed}} under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Ectodermal dysplasia is a rare disorder with defects in {{two or more of}} the following structures: the teeth and the skin and its appendages including hair, nails, eccrine, and sebaceous glands. Anhidrotic ectodermal dysplasia is the most common type of disease. This rare disorder, also known as Christ-Siemens-Touraine syndrome, manifests as a triad of hypotrichosis, asteatosis, and anhidrosis. In view of the rarity of this entity, a classical case of anhidrotic ectodermal dysplasia is reported. We have also provided a review of recent investigations in the area of dental abnormalities in this syndrome. 1...|$|R
30|$|The {{association}} of malignancy with BOOP is an infrequently described clinical entity and mimics various respiratory conditions. In the largest retrospective study describing this phenomenon, 43 patients with an underlying diagnosis of cancer {{were found on}} lung biopsy to have BOOP as an isolated entity. All patients had received therapy including chemotherapy (71 %) or radiotherapy 9 (21 %), only 7 had surgery alone. Two patients who had received extra-thoracic radiation developed BOOP 2 – 3  years after treatment, while others who received thoracic radiation developed BOOP ipsilateral to the radiation port. One case of breast cancer was also reported. Patients with solid organ tumours {{were more likely to}} have nodular or mass like radiographic abnormalities (81 %) rather than diffuse infiltrates (19 %). The opposite pattern was observed in patients with hematologic malignancies (22 vs. 67 %). Most patients recovered on steroids or macrolides but the disease was fatal in 3 patients with haematological malignancies (<b>Mokhtari</b> <b>et</b> <b>al.</b> 2002).|$|R
30|$|Many {{advantages}} such as {{very low}} background current, low cost, large potential window, simple surface renewal process, and easiness of miniaturization of carbon paste electrode (CPE) are widely applicable in both electrochemical studies and electroanalysis. In addition, easy fabrication of the electrode {{can be achieved}} by incorporating different substances during paste preparation which results in the so-called modified electrode with desired composition and predetermined properties (Khoobi A. <b>et</b> <b>al.</b> 2013; <b>Mokhtari</b> A. <b>et</b> <b>al.</b> 2012; Díaz C. <b>et</b> <b>al.</b> 2013; Gholivand M.B. and Mohammadi-Behzad L. 2014; Mazloum-Ardakani M. <b>et</b> <b>al.</b> 2010; Raoof J.B <b>et</b> <b>al.</b> 2007; Dönmez S. <b>et</b> <b>al.</b> 2014).|$|R
30|$|As is well known, {{the real}} world is indeterminate. In real-life projects, the {{activity}} durations may be variational due to many external factors, such as the increase of productivity level and the change of weather. In recent years, many authors have considered the nondeterministic factors for describing the real-life project indeterminacy. In 1985, Wollmer [9] discussed a stochastic version of the deterministic linear TCTP. In 2000, Gutjahr <b>et</b> <b>al.</b> [10] designed a modified stochastic branch-and-bound approach and applied it to a specific stochastic discrete TCTP. Aghaie and Mokhtari [11] described an approach based on ant colony optimization method and Monte Carlo simulation technique for project crashing problem with exponentially distributed activity durations. Zahraie and Tavakolan [12] embedded two concepts of time-cost trade-off and resource leveling and allocation in a stochastic multiobjective optimization model, where fuzzy set theory was applied to represent different options for each activity. Ke <b>et</b> <b>al.</b> [13] built two models for stochastic TCTP with the philosophies of chance-constrained programming and dependent-chance programming. <b>Mokhtari</b> <b>et</b> <b>al.</b> [14] developed a hybrid optimization approach based on cutting plane method and Monte Carlo simulation for stochastic TCTP in PERT networks. Ke <b>et</b> <b>al.</b> [15] modeled stochastic project time-cost trade-offs with time-dependent activity durations.|$|R
30|$|The {{research}} {{articles in this}} special issue analyze models of neural systems at multiple scales. Intracellular calcium signals are important for synapse-to-nucleus communication, and can {{take the form of}} waves which Breit and Queisser (2018) study in a reaction-diffusion model of calcium propagation [7]. At the neuron level, <b>Mokhtari</b> <b>et</b> <b>al.</b> (2018) study how short-term plasticity impacts neural information propagation across synapses, exploring the effect of muscarine treatment on hippocampal neurons [6]. At the microcircuit level, Ferrario <b>et</b> <b>al.</b> (2018) analyze bifurcations that determine transitions between swimming and synchrony modes in a simple model of the Xenopus tadpole spinal central pattern generator (CPG) [8]. Moving to large-scale networks, Barreiro and Ly (2018) derive relationships between pairwise spike count correlations and firing rates in heterogeneous networks, extending linear response theory [5]. Lastly, Hedrick and Zhang (2018) use local stability analysis to study the operational modes of an attractor neural network model of spatial working memory, showing how output patterns depend on conflicting external inputs [9]. These studies demonstrate the wide array of mathematical techniques being developed to understand the dynamics and coding processes of neural systems.|$|R
30|$|The {{subject was}} {{addressed}} by similar {{studies in the}} developing countries. The AVAIL ME study was a Middle Eastern comprehensive evaluation of VTE prophylaxis, conducted to assess the status of anticoagulation practices in seven countries (Taher <b>et</b> <b>al.</b> 2011). Of 2266 patients, 82.9  % were eligible for prophylaxis according to the ACCP 2004 guidelines. Fifty-one percent obtained some form of VTE prophylaxis, but only 37.8  % according to the ACCP guidelines. The study included medical and surgical patients and revealed that adherence to ACCP guidelines was 44  % in the surgical group, {{higher than that of}} the medical group. Later on, the AVAIL ME Extension study (<b>Mokhtari</b> <b>et</b> <b>al.</b> 2011) included ten Middle Eastern and Asian countries and defined the rate of patients receiving appropriate prophylaxis according to ACCP 2008 guidelines. Sixty-eight percent of patients were surgical, and cancer surgery constituted 14.1  % of these patients. Application of VTE prophylaxis guidelines was found only in 32  % of all patients. Thirty-nine percent of all surgical patients followed correctly the guidelines. The rate of patients who did not require or had contraindications to VTE prophylaxis received it in 78 and 66  % respectively. Similar to the ENDORSE study; AVAIL ME was cross-sectional using a 1 -day assessment, so VTE prophylaxis duration appropriateness couldn’t be assessed.|$|R
40|$|Copyright © 2015 Khalida <b>Mokhtari</b> <b>et</b> <b>al.</b> This is an {{open access}} article {{distributed}} under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Maslinic acid (MA) is a natural compound whose structure corresponds to a pentacyclic triterpene. It is abundant in the cuticular lipid layer of olives. MA has many biological and therapeutic properties related to health, including antitumor, anti-inflammatory, antimicrobial, antiparasitic, antihypertensive, and antioxidant activities. However, no studies have been performed to understand the molecular mechanism induced by this compound in melanoma cancer. The objective {{of this study was}} to examine the effect of MA in melanoma (B 16 F 10) cells grown in the presence or absence of fetal bovine serum (FBS). We performed cell proliferation measurements, and the reactive oxygen species (ROS) measurements using dihydrorhodamine 123 (DHR 123) and activities of catalase, glucose 6 -phosphate dehydrogenase, glutathione S-transferase, and superoxide dismutase. These changes were corroborated by expression assays. FBS absence reduced cell viability decreasing IC 50 values of MA. The DHR 123 data showed an increase in the ROS level in the absence of FBS. Furthermore, MA had an antioxidant effect at lower assayed levels measured a...|$|R
40|$|International audienceThe paper {{presents}} {{extensions of}} the single-matrix formulation (<b>Mokhtari</b> <b>et</b> <b>al.,</b> 2008, Speech Comm. 50 (3) 179 – 190) that enable self-oscillation models of vocal folds, including glottal chink, {{to be connected to}} the vocal tract. They also integrate the case of a local division of the main air path into two lateral channels, as it may occur during the production of lateral consonants. Provided extensions are detailed by a reformulation of the acoustic conditions at the glottis, and at the upstream and downstream connections of bilateral channels. The simulation framework is validated through numerical simulations. The introduction of an antiresonance in the transfer function due to the presence of asymmetric bilateral channels is confirmed by the simulations. The frequency of the antiresonance agrees with the theoretical predictions. Simulations of static vowels reveal that the behavior of the vocal folds is qualitatively similar whether they are connected to the single-matrix formulation or to the classic reflection-type line analog model. Finally, the acoustic effect of the glottal chink on the production of vowels is highlighted by the simulations: the shortening of the vibrating part of the vocal folds lowers the amplitude of the glottal flow, and therefore lowers the global acoustic level radiated at the lips. It also introduces an offset in the glottal flow waveform...|$|R
30|$|After {{the devastating}} Bam earthquake, the National Center for Earthquake Prediction (NCEP) was {{established}} by governmental decree at the International Institute of Earthquake Engineering and Seismology (IIEES). As part of the NCEP, a test site {{has been established in}} the Alborz mountain region for earthquake monitoring and possible future prediction/precursor detection purposes. The proximity of the test site to the capital of Iran—Tehran—with its high population density, low frequency but high magnitude earthquake occurrence, and active faults with historical earthquake events are the main criteria for this selection (Mokhtari 2010). An aftershock monitoring system (local dense seismic network) was established for {{a better understanding of the}} seismo-tectonic activity and to identify the main fault responsible for the earthquake occurrences (Tatar <b>et</b> <b>al.</b> 2004). These developments emphasized the necessity of preparedness and the implementation of an earthquake early warning system (EEWS), and a better understanding of precursory seismic activities in Iran. In addition, the requirement of having more seismic stations throughout Iran was recognized. An EEWS was implemented successfully in countries like Mexico and Japan. EEWS is also under advanced development in Turkey, Romania, the United States, Italy, and Taiwan and mainland China (Allen <b>et</b> <b>al.</b> 2009; <b>Mokhtari</b> 2010). The success of EEWS in Iran will be strengthened by a national long-term support, multidisciplinary approaches, use of different technologies, international collaboration, earthquake disaster risk awareness, public education and disaster preparedness, learning from earthquake disasters, and development of a culture of resilience and earthquake disaster risk reduction, among the communities and society (<b>Mokhtari</b> 2010; Ibrion <b>et</b> <b>al.</b> 2015 c).|$|R
30|$|Several {{major issues}} {{were found for}} both knee-to-knee and knee-to-ankle mosaicplasty procedure. The type of study was poorly scored and {{included}} small sample sizes (n[*]<[*] 20) (Reddy <b>et</b> <b>al.</b> 2007; Al-Shaikh <b>et</b> <b>al.</b> 2002; Atik <b>et</b> <b>al.</b> 2005; Gautier <b>et</b> <b>al.</b> 2002; Kock <b>et</b> <b>al.</b> 2010; Koulalis <b>et</b> <b>al.</b> 2004; Lee <b>et</b> <b>al.</b> 2003; Quarch <b>et</b> <b>al.</b> 2014; Reverte-Vinaixa <b>et</b> <b>al.</b> 2013; Valderrabano <b>et</b> <b>al.</b> 2009). In addition, the procedure for assessing the outcomes (Reddy <b>et</b> <b>al.</b> 2007; Al-Shaikh <b>et</b> <b>al.</b> 2002; Atik <b>et</b> <b>al.</b> 2005; Baltzer & Arnold 2005; de l'Escalopier <b>et</b> <b>al.</b> 2015; Gautier <b>et</b> <b>al.</b> 2002; Hangody <b>et</b> <b>al.</b> 2001 a; Hangody <b>et</b> <b>al.</b> 2008; Jakob <b>et</b> <b>al.</b> 2002; Kim <b>et</b> <b>al.</b> 2012; Koulalis <b>et</b> <b>al.</b> 2004; Lee <b>et</b> <b>al.</b> 2003; Quarch <b>et</b> <b>al.</b> 2014) and {{the description of the}} subject selection process (Hangody <b>et</b> <b>al.</b> 2010; Espregueira-Mendes <b>et</b> <b>al.</b> 2012; Reddy <b>et</b> <b>al.</b> 2007; Ahmad & Jones 2015; Al-Shaikh <b>et</b> <b>al.</b> 2002; Atik <b>et</b> <b>al.</b> 2005; Baltzer & Arnold 2005; de l'Escalopier <b>et</b> <b>al.</b> 2015; Gautier <b>et</b> <b>al.</b> 2002; Hangody <b>et</b> <b>al.</b> 2001 a; Hangody <b>et</b> <b>al.</b> 2008; Jakob <b>et</b> <b>al.</b> 2002; Kim <b>et</b> <b>al.</b> 2012; Kock <b>et</b> <b>al.</b> 2010; Koulalis <b>et</b> <b>al.</b> 2004; Lee <b>et</b> <b>al.</b> 2003; Quarch <b>et</b> <b>al.</b> 2014; Reverte-Vinaixa <b>et</b> <b>al.</b> 2013; Valderrabano <b>et</b> <b>al.</b> 2009; Kreuz <b>et</b> <b>al.</b> 2006) were also poorly reported across the included original studies.|$|R
30|$|Other {{themes were}} less well-represented by checklists: 13 checklists (52 %) {{contained}} no items on “Team working”(Lee <b>et</b> <b>al.</b> 2009; Lobo <b>et</b> <b>al.</b> 2005; Millington <b>et</b> <b>al.</b> 2009; Murphy <b>et</b> <b>al.</b> 2008; Rosen <b>et</b> <b>al.</b> 2009; Ramakrishna <b>et</b> <b>al.</b> 2005; Blaivas and Adhikari 2009; Carvalho 2007; Stone <b>et</b> <b>al.</b> 2010; Kilbourne <b>et</b> <b>al.</b> 2009; Coopersmith <b>et</b> <b>al.</b> 2002; Xiao <b>et</b> <b>al.</b> 2007; Yilmaz <b>et</b> <b>al.</b> 2007); 14 checklists (56 %) contained no items on “Communication {{and working with}} the patient” (Berenholtz <b>et</b> <b>al.</b> 2004; Blaivas and Adhikari 2009; Britt <b>et</b> <b>al.</b> 2009; Carvalho 2007; Coopersmith <b>et</b> <b>al.</b> 2002; Kilbourne <b>et</b> <b>al.</b> 2009; Lobo <b>et</b> <b>al.</b> 2005; McKee <b>et</b> <b>al.</b> 2008; Millington <b>et</b> <b>al.</b> 2009; Papadimos <b>et</b> <b>al.</b> 2008; Stone <b>et</b> <b>al.</b> 2010; Velmahos <b>et</b> <b>al.</b> 2004; Xiao <b>et</b> <b>al.</b> 2007; Yilmaz <b>et</b> <b>al.</b> 2007); seven checklists (28 %) contained no items on “Post-procedure” (Ramakrishna <b>et</b> <b>al.</b> 2005; Blaivas and Adhikari 2009; Carvalho 2007; Stone <b>et</b> <b>al.</b> 2010; Kilbourne <b>et</b> <b>al.</b> 2009; Xiao <b>et</b> <b>al.</b> 2007; Yilmaz <b>et</b> <b>al.</b> 2007); seven checklists (28 %) contained no items on “Safety” (Berenholtz <b>et</b> <b>al.</b> 2004; McKee <b>et</b> <b>al.</b> 2008; Millington <b>et</b> <b>al.</b> 2009; Papadimos <b>et</b> <b>al.</b> 2008; Ramakrishna <b>et</b> <b>al.</b> 2005; Xiao <b>et</b> <b>al.</b> 2007; Yilmaz <b>et</b> <b>al.</b> 2007); and six checklists (24 %) contained no items on “Procedural competence” (Coopersmith <b>et</b> <b>al.</b> 2002; Costello <b>et</b> <b>al.</b> 2008; Lobo <b>et</b> <b>al.</b> 2005; McKee <b>et</b> <b>al.</b> 2008; Xiao <b>et</b> <b>al.</b> 2007; Yilmaz <b>et</b> <b>al.</b> 2007).|$|R
30|$|One {{hundred and}} twenty-eight {{articles}} described 350 cases of NOVC bacteraemia involving 347 patients, 3 of whom {{presented with a}} second episode (Additional file 1 : Table S 1) (Petsaris <b>et</b> <b>al.</b> 2010; Mannion and Mellor 1986; Lai <b>et</b> <b>al.</b> 2012; Morris <b>et</b> <b>al.</b> 1981; Anderson <b>et</b> <b>al.</b> 2004; Pierce <b>et</b> <b>al.</b> 2000; Hlady and Klontz 1996; Magnusson and Pegg 1996; Robins-Browne <b>et</b> <b>al.</b> 1977; Eltahawy <b>et</b> <b>al.</b> 2004; Marcenac <b>et</b> <b>al.</b> 1991; Ferreira <b>et</b> <b>al.</b> 2012; Zarate <b>et</b> <b>al.</b> 2011; Goei and Karthigasu 1978; Trubiano <b>et</b> <b>al.</b> 2014; Heath <b>et</b> <b>al.</b> 2001; Guard <b>et</b> <b>al.</b> 1980; Hsu <b>et</b> <b>al.</b> 2013; Huhulescu <b>et</b> <b>al.</b> 2007; Halabi <b>et</b> <b>al.</b> 1997; Berghmans <b>et</b> <b>al.</b> 2002; Kadkhoda <b>et</b> <b>al.</b> 2012; Burns <b>et</b> <b>al.</b> 1989; Ramsingh 1998; Briceno <b>et</b> <b>al.</b> 2009; Young <b>et</b> <b>al.</b> 1991; Lu <b>et</b> <b>al.</b> 2014; Farmachidi <b>et</b> <b>al.</b> 2003; Chong <b>et</b> <b>al.</b> 1985; Choi <b>et</b> <b>al.</b> 2003; Dalsgaard <b>et</b> <b>al.</b> 2000; Marek <b>et</b> <b>al.</b> 2013; Aguinaga <b>et</b> <b>al.</b> 2009; Forné <b>et</b> <b>al.</b> 1987; Prats <b>et</b> <b>al.</b> 1975; Lopez-Brea <b>et</b> <b>al.</b> 1985; Mirelis <b>et</b> <b>al.</b> 1987; Royo <b>et</b> <b>al.</b> 1993; Mauri <b>et</b> <b>al.</b> 1987; Esparcia <b>et</b> <b>al.</b> 2000; Fernández <b>et</b> <b>al.</b> 2000; Lantero <b>et</b> <b>al.</b> 1984; Folgueira <b>et</b> <b>al.</b> 1991; Fernández-Monrás <b>et</b> <b>al.</b> 1990; Catalá Barceló MT 1998; Fernández-Natal and Alcoba-Leza 1996; Calduch Broseta JV 2003; Rabadan and Vilalta 1989; Rubin <b>et</b> <b>al.</b> 1981; Nedunchezian <b>et</b> <b>al.</b> 1994; Pitrak and Gindorf 1989; Bonner <b>et</b> <b>al.</b> 1983; Newman <b>et</b> <b>al.</b> 1993; Namdari <b>et</b> <b>al.</b> 2000; Patel <b>et</b> <b>al.</b> 2009; Wagner <b>et</b> <b>al.</b> 1995; Siegel and Rogers 1982; McCleskey <b>et</b> <b>al.</b> 1986; Florman <b>et</b> <b>al.</b> 1990; West <b>et</b> <b>al.</b> 1998; Klontz 1990; Hughes <b>et</b> <b>al.</b> 1978; Restrepo <b>et</b> <b>al.</b> 2006; Safrin <b>et</b> <b>al.</b> 1988; Fearrington <b>et</b> <b>al.</b> 1974; Shannon and Kimbrough 2006; Platia and Vosti 1980; Kontoyiannis <b>et</b> <b>al.</b> 1995; Shelton <b>et</b> <b>al.</b> 1993; Crump <b>et</b> <b>al.</b> 2003; Naidu <b>et</b> <b>al.</b> 1993; Morgan <b>et</b> <b>al.</b> 1985; Lukinmaa <b>et</b> <b>al.</b> 2006; Blanche and Sicard 1994; Moinard <b>et</b> <b>al.</b> 1989; Laudat <b>et</b> <b>al.</b> 1997; Raultin and de La Roy, 1981; Couzigou <b>et</b> <b>al.</b> 2007; Issack <b>et</b> <b>al.</b> 2008; Kerketta <b>et</b> <b>al.</b> 2002; Thomas <b>et</b> <b>al.</b> 1996; Lalitha <b>et</b> <b>al.</b> 1986; George <b>et</b> <b>al.</b> 2013; Raju <b>et</b> <b>al.</b> 1990; Khan <b>et</b> <b>al.</b> 2013; Toeg <b>et</b> <b>al.</b> 1990; Rudensky <b>et</b> <b>al.</b> 1993; Farina <b>et</b> <b>al.</b> 1999; Piersimoni <b>et</b> <b>al.</b> 1991; Ismail <b>et</b> <b>al.</b> 2001; Dhar <b>et</b> <b>al.</b> 1989, 2004; Phetsouvanh <b>et</b> <b>al.</b> 2008; Feghali and Adib 2011; Tan <b>et</b> <b>al.</b> 1994; Deris and Leow 2009; Whittaker 2013; Stypulkowska-Misiurewicz <b>et</b> <b>al.</b> 2006; Albuquerque <b>et</b> <b>al.</b> 2013; El-Hiday and Khan 2006; Khan <b>et</b> <b>al.</b> 2007; Strumbelj <b>et</b> <b>al.</b> 2005; Wiström 1989; Lin <b>et</b> <b>al.</b> 1996; Ko <b>et</b> <b>al.</b> 1998; Lee <b>et</b> <b>al.</b> 1993; Chang-Chien 2006; Tsai and Huang 2009; Chan <b>et</b> <b>al.</b> 1994; Yang <b>et</b> <b>al.</b> 2008; Cheng <b>et</b> <b>al.</b> 2004; Tsai <b>et</b> <b>al.</b> 2004; Wang <b>et</b> <b>al.</b> 1991; Laosombat <b>et</b> <b>al.</b> 1996; Punpanich <b>et</b> <b>al.</b> 2011; Thisyakorn and Reinprayoon 1990; Luxsameesathaporn <b>et</b> <b>al.</b> 2012; Suankratay <b>et</b> <b>al.</b> 2001; Wiwatworapan and Insiripong 2008; Boukadida <b>et</b> <b>al.</b> 1993; Lan <b>et</b> <b>al.</b> 2014; Geneste <b>et</b> <b>al.</b> 1995; Yang <b>et</b> <b>al.</b> 2011; Thomas <b>et</b> <b>al.</b> 2007; Ou <b>et</b> <b>al.</b> 2003; Lee <b>et</b> <b>al.</b> 2007; Thamlikitkul 1990; Jesudason <b>et</b> <b>al.</b> 1991). The majority of articles were case reports, the largest series including 69 cases of bacteraemia (Ou <b>et</b> <b>al.</b> 2003). The first case was described in the USA in 1974 (Fearrington <b>et</b> <b>al.</b> 1974). One hundred and fifty-six cases (45  %) originated from Taiwan, 60 / 350 (20  %) from the USA and 21 / 350 (6  %) from Spain. Although NOVC strains are frequently found in coastal waters, only two cases {{have been reported in}} Africa. Two possible explanations are under-diagnosis due to lack of resources, and the non reporting of clinical cases. Including our own case report, 12 cases of NOVC bacteraemia have been published in France, in summer or autumn, including four imported cases from Tunisia (2), Morocco (1) and Senegal (1) (Farmachidi <b>et</b> <b>al.</b> 2003; Blanche and Sicard 1994; Moinard <b>et</b> <b>al.</b> 1989; Laudat <b>et</b> <b>al.</b> 1997; Raultin and de La Roy, 1981; Couzigou <b>et</b> <b>al.</b> 2007).|$|R
30|$|Because of its {{popularity}} for hybrid rice production, both {{the parents and}} the hybrid have been extensively used for genetics and genomics studies during the past four decades. In the first report of resequencing multiple varieties, both parents of SY 63 were used among 20 diverse varieties for resequencing of 100  Mb of the unique fraction of the genome (McNally <b>et</b> <b>al.</b> 2009). It was found that large components of the japonica genome were introgressed into both of the parents, specifically, on chromosome 1 of ZS 97 and chromosome 6 of MH 63. Those components contribute greatly to genes controlling heterosis (Yu <b>et</b> <b>al.</b> 1997; Hua <b>et</b> <b>al.</b> 2002; Li <b>et</b> <b>al.</b> 2008; Li <b>et</b> <b>al.</b> 2008; Zhou <b>et</b> <b>al.</b> 2012; Shen <b>et</b> <b>al.</b> 2014; Zhu <b>et</b> <b>al.</b> 2016). Other studies on the association of QTLs and traits included plant height (Xing <b>et</b> <b>al.</b> 2001; Guo <b>et</b> <b>al.</b> 2002; Yu <b>et</b> <b>al.</b> 2002; Guo <b>et</b> <b>al.</b> 2003; Shen <b>et</b> <b>al.</b> 2014), heading date (Xing <b>et</b> <b>al.</b> 2001; Guo <b>et</b> <b>al.</b> 2002; Guo <b>et</b> <b>al.</b> 2003; Yu <b>et</b> <b>al.</b> 2002; Zhu <b>et</b> <b>al.</b> 2016), fertility-restoring genes (He <b>et</b> <b>al.</b> 2002), seedling traits (Cui <b>et</b> <b>al.</b> 2002; Cui <b>et</b> <b>al.</b> 2002; Cui <b>et</b> <b>al.</b> 2010; Zhu <b>et</b> <b>al.</b> 2016), leaf shape (Li <b>et</b> <b>al.</b> 2008), grain quality (Tan <b>et</b> <b>al.</b> 1999; Tan <b>et</b> <b>al.</b> 2001; Xing <b>et</b> <b>al.</b> 2001; Ge <b>et</b> <b>al.</b> 2005; Zheng <b>et</b> <b>al.</b> 2008 a; Zheng <b>et</b> <b>al.</b> 2008 b), yield-related traits (Yu <b>et</b> <b>al.</b> 1997; Guo <b>et</b> <b>al.</b> 2002; Hua <b>et</b> <b>al.</b> 2002; Xing <b>et</b> <b>al.</b> 2002; Cui <b>et</b> <b>al.</b> 2003; Guo <b>et</b> <b>al.</b> 2003; Xue <b>et</b> <b>al.</b> 2008; Li <b>et</b> <b>al.</b> 2008; Xing <b>et</b> <b>al.</b> 2008; Liu <b>et</b> <b>al.</b> 2010; Liu <b>et</b> <b>al.</b> 2010; Zhou <b>et</b> <b>al.</b> 2012), disease resistance (Han <b>et</b> <b>al.</b> 2002; Chen <b>et</b> <b>al.</b> 2002; Yang <b>et</b> <b>al.</b> 2003; Li <b>et</b> <b>al.</b> 2010; Kou <b>et</b> <b>al.</b> 2010), tolerance of nitrogen deficiency (Lian <b>et</b> <b>al.</b> 2005; Wei <b>et</b> <b>al.</b> 2012), and drought tolerance (Lian <b>et</b> <b>al.</b> 2005; Wei <b>et</b> <b>al.</b> 2012).|$|R
30|$|Inter-rater {{reliability}} was reported for 12 (48 %) {{of the studies}} (Barsuk <b>et</b> <b>al.</b> 2009 a; Barsuk <b>et</b> <b>al.</b> 2009 c; Dong <b>et</b> <b>al.</b> 2010; Evans <b>et</b> <b>al.</b> 2009; Huang <b>et</b> <b>al.</b> 2009; Lee <b>et</b> <b>al.</b> 2009; Millington <b>et</b> <b>al.</b> 2009; Murphy <b>et</b> <b>al.</b> 2008; Rosen <b>et</b> <b>al.</b> 2009; Kilbourne <b>et</b> <b>al.</b> 2009; Stone <b>et</b> <b>al.</b> 2010; Xiao <b>et</b> <b>al.</b> 2007), reporting a range of reliability coefficients and absolute agreement [range 0.43 (Millington <b>et</b> <b>al.</b> 2009) to 0.97 (Evans <b>et</b> <b>al.</b> 2009)]. Only 12 studies (48 %) specified the process used for content validation (Velmahos <b>et</b> <b>al.</b> 2004; Barsuk <b>et</b> <b>al.</b> 2009 a; Barsuk <b>et</b> <b>al.</b> 2009 c; Costello <b>et</b> <b>al.</b> 2008; Dong <b>et</b> <b>al.</b> 2010; Evans <b>et</b> <b>al.</b> 2009; Huang <b>et</b> <b>al.</b> 2009; Lee <b>et</b> <b>al.</b> 2009; Rosen <b>et</b> <b>al.</b> 2009; Wall <b>et</b> <b>al.</b> 2005; Kilbourne <b>et</b> <b>al.</b> 2009; Coopersmith <b>et</b> <b>al.</b> 2002).|$|R
30|$|To sputter calcium orthophosphates, {{several types}} of the {{physical}} vapor deposition techniques are used, such as ion beam (Stevenson <b>et</b> <b>al.</b> 1989; Barthell <b>et</b> <b>al.</b> 1989; Ong <b>et</b> <b>al.</b> 1991, 1992, 1994; Yoshinari <b>et</b> <b>al.</b> 1994; Cui <b>et</b> <b>al.</b> 1997; Kim <b>et</b> <b>al.</b> 1998; Luo <b>et</b> <b>al.</b> 1999; Choi <b>et</b> <b>al.</b> 2000; Wang <b>et</b> <b>al.</b> 2001; Hamdi and Ide-Ektessabi 2003; Lee <b>et</b> <b>al.</b> 2003; Fujihara <b>et</b> <b>al.</b> 2004; Lee <b>et</b> <b>al.</b> 2005 b; Rabiei <b>et</b> <b>al.</b> 2006; Lee <b>et</b> <b>al.</b> 2007 a; Blalock <b>et</b> <b>al.</b> 2007), radio-frequency (RF) magnetron (Cooley <b>et</b> <b>al.</b> 1992; Yamashita <b>et</b> <b>al.</b> 1994; Jansen <b>et</b> <b>al.</b> 1993; Wolke <b>et</b> <b>al.</b> 1994; van Dijk <b>et</b> <b>al.</b> 1995, 1996; Wolke <b>et</b> <b>al.</b> 1998, 2003; Nelea <b>et</b> <b>al.</b> 2003, 2004; Feddes <b>et</b> <b>al.</b> 2003 a, 2003 b; Ding 2003; Yamaguchi <b>et</b> <b>al.</b> 2006; Wan <b>et</b> <b>al.</b> 2007; Ozeki <b>et</b> <b>al.</b> 2007; Ueda <b>et</b> <b>al.</b> 2007; Snyders <b>et</b> <b>al.</b> 2008; Ievlev <b>et</b> <b>al.</b> 2008; Toque <b>et</b> <b>al.</b> 2009), pulsed laser (Nelea <b>et</b> <b>al.</b> 2000, 2002, 2004; Cotell <b>et</b> <b>al.</b> 1992, Cotell 1993; Torrisi and Setola 1993; Cotell 1993; Singh <b>et</b> <b>al.</b> 1994; Wang <b>et</b> <b>al.</b> 1997; Hontsu <b>et</b> <b>al.</b> 1997; Fernández-Pradas <b>et</b> <b>al.</b> 1998, 1999, 2001; Mayor <b>et</b> <b>al.</b> 1998; Arias <b>et</b> <b>al.</b> 1998; Craciun <b>et</b> <b>al.</b> 1999; Fernandez-Pradas <b>et</b> <b>al.</b> 1999; Zeng <b>et</b> <b>al.</b> 2000; Cleries <b>et</b> <b>al.</b> 2000 a; Nelea <b>et</b> <b>al.</b> 2000; Zeng and Lacefield 2000; Fernandez-Pradas <b>et</b> <b>al.</b> 2001; Nelea <b>et</b> <b>al.</b> 2002; Socol <b>et</b> <b>al.</b> 2004; Kim <b>et</b> <b>al.</b> 2005 a; Bigi <b>et</b> <b>al.</b> 2005 b; Koch <b>et</b> <b>al.</b> 2007; Kim <b>et</b> <b>al.</b> 2007 a; Paital and Dahotre 2008; Paital <b>et</b> <b>al.</b> 2009; Dinda <b>et</b> <b>al.</b> 2009; Tri and Chua 2009; Sygnatowicz and Tiwari 2009), diode, direct current and reactive sputtering or deposition (Massaro <b>et</b> <b>al.</b> 2001). The physical and aggregate states of the calcium orthophosphate source might influence the deposition kinetics. For example, the deposition rate of HA {{was found to be}} much higher in a solid plate target than in a powder lump target, owing to the difference of apparent density approximately 75 % and approximately 18 %, respectively (Wan <b>et</b> <b>al.</b> 2007).|$|R
30|$|Recently, genetic {{studies of}} IPMN lead to {{discover}} mutations of new genes, including GNAS, and RNF 43 (Macgregor-Das and Iacobuzio-Donahue 2013; Reid <b>et</b> <b>al.</b> 2014). In {{addition to the}} previously known genetic alteration such as KRAS, these gene mutations open a new viewpoint {{in the field of}} the molecular pathogenesis of IPMN. Nevertheless, the frequencies and clinicopathologic significances of KRAS, GNAS, and RNF 43 have not been clearly delineated. Activating GNAS mutation at codon 201 has been identified in IPMNs of the pancreas, which runs from 36 to 79  % (Amato <b>et</b> <b>al.</b> 2014; Hosoda <b>et</b> <b>al.</b> 2015; Ideno <b>et</b> <b>al.</b> 2015; Kanda <b>et</b> <b>al.</b> 2013; Kuboki <b>et</b> <b>al.</b> 2015; Lee <b>et</b> <b>al.</b> 2014; Siddiqui <b>et</b> <b>al.</b> 2013; Singhi <b>et</b> <b>al.</b> 2014; Takano <b>et</b> <b>al.</b> 2014; Tan <b>et</b> <b>al.</b> 2015; Wu <b>et</b> <b>al.</b> 2011 b). Moreover, the wide extreme diversity of KRAS mutation in IPMN patients, ranged from 13 to 100  %, has been observed (Amato <b>et</b> <b>al.</b> 2014; Chadwick <b>et</b> <b>al.</b> 2009; Chang <b>et</b> <b>al.</b> 2014; Fritz <b>et</b> <b>al.</b> 2009; Furukawa <b>et</b> <b>al.</b> 2005; Hosoda <b>et</b> <b>al.</b> 2015; Ideno <b>et</b> <b>al.</b> 2015; Jang <b>et</b> <b>al.</b> 2009; Kaino <b>et</b> <b>al.</b> 1999; Kitago <b>et</b> <b>al.</b> 2004; Kobayashi <b>et</b> <b>al.</b> 2008; Kondo <b>et</b> <b>al.</b> 1997; Kuboki <b>et</b> <b>al.</b> 2015; Lee <b>et</b> <b>al.</b> 2014; Lubezky <b>et</b> <b>al.</b> 2011; Mizuno <b>et</b> <b>al.</b> 2010; Mohri <b>et</b> <b>al.</b> 2012; Mueller <b>et</b> <b>al.</b> 2003; Mulligan <b>et</b> <b>al.</b> 1999; Nakata <b>et</b> <b>al.</b> 2002; Paal <b>et</b> <b>al.</b> 1999; Raimondo <b>et</b> <b>al.</b> 2002; Schönleben <b>et</b> <b>al.</b> 2008; Sessa <b>et</b> <b>al.</b> 1994; Siddiqui <b>et</b> <b>al.</b> 2013; Singhi <b>et</b> <b>al.</b> 2014; Tada <b>et</b> <b>al.</b> 1991; Takano <b>et</b> <b>al.</b> 2014; Tan <b>et</b> <b>al.</b> 2015; Uemura <b>et</b> <b>al.</b> 2003; Wada <b>et</b> <b>al.</b> 2004; Wu <b>et</b> <b>al.</b> 2011 b; Yoshizawa <b>et</b> <b>al.</b> 2002). The frequency of RNF 43 mutation was ranged from 14 to 75  % (Amato <b>et</b> <b>al.</b> 2014; Sakamoto <b>et</b> <b>al.</b> 2015; Tan <b>et</b> <b>al.</b> 2015; Wu <b>et</b> <b>al.</b> 2011 a).|$|R
30|$|The donor-sites {{used for}} the {{osteochondral}} graft harvesting varied across the studies, including: margins of the medial femoral trochlea (condyle) (Hangody <b>et</b> <b>al.</b> 2010; Gudas <b>et</b> <b>al.</b> 2005; Ahmad & Jones 2015; de l'Escalopier <b>et</b> <b>al.</b> 2015; Gautier <b>et</b> <b>al.</b> 2002; Hangody <b>et</b> <b>al.</b> 2001 a; Hangody <b>et</b> <b>al.</b> 2008; Jakob <b>et</b> <b>al.</b> 2002; Lee <b>et</b> <b>al.</b> 2003; Quarch <b>et</b> <b>al.</b> 2014); margins of the lateral femoral trochlea (condyle) (Hangody <b>et</b> <b>al.</b> 2010; Reddy <b>et</b> <b>al.</b> 2007; Gudas <b>et</b> <b>al.</b> 2005; Ahmad & Jones 2015; Al-Shaikh <b>et</b> <b>al.</b> 2002; Baltzer & Arnold 2005; de l'Escalopier <b>et</b> <b>al.</b> 2015; Gautier <b>et</b> <b>al.</b> 2002; Hangody <b>et</b> <b>al.</b> 2001 a; Hangody <b>et</b> <b>al.</b> 2008; Jakob <b>et</b> <b>al.</b> 2002; Kim <b>et</b> <b>al.</b> 2012; Kock <b>et</b> <b>al.</b> 2010; Koulalis <b>et</b> <b>al.</b> 2004; Reverte-Vinaixa <b>et</b> <b>al.</b> 2013; Valderrabano <b>et</b> <b>al.</b> 2009); minimal weight-bearing areas of the patellofemoral joint (Atik <b>et</b> <b>al.</b> 2005); intercondylar notch area (Reddy <b>et</b> <b>al.</b> 2007; Atik <b>et</b> <b>al.</b> 2005; Hangody <b>et</b> <b>al.</b> 2008); upper tibio-fibular joint (Espregueira-Mendes <b>et</b> <b>al.</b> 2012).|$|R
30|$|The {{selenium}} nanoparticles are bestowed with multifaceted biological properties mainly due {{its high}} bioavailability and biocompatibility; and low cytotoxicity (Shakibaie <b>et</b> <b>al.</b> 2010; Wang <b>et</b> <b>al.</b> 2010, 2013). A {{wide variety of}} properties shown by selenium nanoparticles are free radical scavenging (Huang <b>et</b> <b>al.</b> 2003), antioxidant (Forootanfar <b>et</b> <b>al.</b> 2014; Kong <b>et</b> <b>al.</b> 2014; Mittal <b>et</b> <b>al.</b> 2014; Ramya <b>et</b> <b>al.</b> 2015; Rezvanfar <b>et</b> <b>al.</b> 2013; Torres <b>et</b> <b>al.</b> 2012; Wang <b>et</b> <b>al.</b> 2013), chemoprotection against chemotherapy-induced reproductive toxicity (Rezvanfar <b>et</b> <b>al.</b> 2013) and UV-induced DNA damage (Prasad <b>et</b> <b>al.</b> 2013), immunomodulatory, anti-inflammatory (Wang <b>et</b> <b>al.</b> 2014), nanomedicinal (Shen <b>et</b> <b>al.</b> 2008), chemotherapeutic and chemoprevention against human melanoma and hepatoma cancers (Chen <b>et</b> <b>al.</b> 2008; Estevez <b>et</b> <b>al.</b> 2014; Peng <b>et</b> <b>al.</b> 2007), biofortification (Durán <b>et</b> <b>al.</b> 2015), and antitumor and anticancer (Jia <b>et</b> <b>al.</b> 2015; Kumar <b>et</b> <b>al.</b> 2015; Mittal <b>et</b> <b>al.</b> 2014; Ren <b>et</b> <b>al.</b> 2013) activities. Other applications include antibacterial, antibiofilm (Bartůněk <b>et</b> <b>al.</b> 2015; Hariharan <b>et</b> <b>al.</b> 2012; Huang <b>et</b> <b>al.</b> 2016; Mittal <b>et</b> <b>al.</b> 2014; Ramya <b>et</b> <b>al.</b> 2015; Shakibaie <b>et</b> <b>al.</b> 2015; Tran and Webster 2011; Wang and Webster 2013), antifungal, antiprotozoan, antitapeworm (Bartůněk <b>et</b> <b>al.</b> 2015), antiviral, wound healing (Ramya <b>et</b> <b>al.</b> 2015), and cytotoxic (Forootanfar <b>et</b> <b>al.</b> 2014; Ramya <b>et</b> <b>al.</b> 2015) activities. Other non-biological activities such as zinc adsorption (Jain <b>et</b> <b>al.</b> 2015), mercury sequestration (Fellowes <b>et</b> <b>al.</b> 2011; Jiang <b>et</b> <b>al.</b> 2012), biosensing of H 2 O 2 (Wang <b>et</b> <b>al.</b> 2010), solar cell (Panahi-Kalamuei <b>et</b> <b>al.</b> 2014), and photocatalysis (Triantis <b>et</b> <b>al.</b> 2009; Yang <b>et</b> <b>al.</b> 2008) are also reported.|$|R
30|$|Although breast {{reconstruction}} {{rates have}} increased over time, they remain relatively low, ranging from 5 to 42  % in population-based and institution-based studies (Brennan and Spillane 2013; Platt <b>et</b> <b>al.</b> 2011; Wilkins and Alderman 2004). These {{studies have found}} that reconstruction rates are significantly lower in African American compared to Caucasian women (Alderman <b>et</b> <b>al.</b> 2009, 2011; Butler <b>et</b> <b>al.</b> 2015; Greenberg <b>et</b> <b>al.</b> 2008; Hershman <b>et</b> <b>al.</b> 2012; Katz <b>et</b> <b>al.</b> 2005; Merchant <b>et</b> <b>al.</b> 2015; Morrow <b>et</b> <b>al.</b> 2005; Reuben <b>et</b> <b>al.</b> 2009; Rosson <b>et</b> <b>al.</b> 2008; Rowland <b>et</b> <b>al.</b> 2000; Tseng <b>et</b> <b>al.</b> 2004; Yang <b>et</b> <b>al.</b> 2013 a, b), a disparity that has been attributed to racial differences in access to breast reconstructive services (Agarwal <b>et</b> <b>al.</b> 2011; Enewold <b>et</b> <b>al.</b> 2014; Greenberg <b>et</b> <b>al.</b> 2008; Katz <b>et</b> <b>al.</b> 2005; Offodile <b>et</b> <b>al.</b> 2015; Rowland <b>et</b> <b>al.</b> 1993; Wexelman <b>et</b> <b>al.</b> 2014) secondary to lower socioeconomic status (Alderman <b>et</b> <b>al.</b> 2003; Greenberg <b>et</b> <b>al.</b> 2008; Joslyn 2005; Katz <b>et</b> <b>al.</b> 2005; Kruper <b>et</b> <b>al.</b> 2011 a; Offodile <b>et</b> <b>al.</b> 2015; Wexelman <b>et</b> <b>al.</b> 2014) and no or inadequate insurance (Alderman <b>et</b> <b>al.</b> 2006; Bradley <b>et</b> <b>al.</b> 2012; Enewold <b>et</b> <b>al.</b> 2014; Wexelman <b>et</b> <b>al.</b> 2014).|$|R
30|$|High {{rates of}} co-occurrence of bipolar {{disorder}} (BD) and eating disorders (EDs) are well documented (Jen <b>et</b> <b>al.</b> 2013; McElroy <b>et</b> <b>al.</b> 2011, 2013, 2016; Wildes <b>et</b> <b>al.</b> 2008). EDs are more prevalent among females compared to males with BD (Jen <b>et</b> <b>al.</b> 2013; McElroy <b>et</b> <b>al.</b> 2011, 2016; Seixas <b>et</b> <b>al.</b> 2012) {{and have been}} associated with more challenging bipolar course, including earlier onset age (Brietzke <b>et</b> <b>al.</b> 2011; Jen <b>et</b> <b>al.</b> 2013; Lunde <b>et</b> <b>al.</b> 2009; McElroy <b>et</b> <b>al.</b> 2011, 2016), more depressive and mood episodes (Brietzke <b>et</b> <b>al.</b> 2011; Lunde <b>et</b> <b>al.</b> 2009; McElroy <b>et</b> <b>al.</b> 2011), rapid cycling (Fornaro <b>et</b> <b>al.</b> 2010; McElroy <b>et</b> <b>al.</b> 2011, 2016), depressive symptoms (Jen <b>et</b> <b>al.</b> 2013; Seixas <b>et</b> <b>al.</b> 2012; Wildes <b>et</b> <b>al.</b> 2007, 2008), suicide attempts (Brietzke <b>et</b> <b>al.</b> 2011; McElroy <b>et</b> <b>al.</b> 2011, 2013, 2016), weight disturbance (McElroy <b>et</b> <b>al.</b> 2011, 2013, 2016; Wildes <b>et</b> <b>al.</b> 2007, 2008), and psychiatric comorbidities (Seixas <b>et</b> <b>al.</b> 2012), including lifetime anxiety (Brietzke <b>et</b> <b>al.</b> 2011; Jen <b>et</b> <b>al.</b> 2013; McElroy <b>et</b> <b>al.</b> 2013, 2016) and alcohol/substance use disorders (Brietzke <b>et</b> <b>al.</b> 2011; Fornaro <b>et</b> <b>al.</b> 2010; Jen <b>et</b> <b>al.</b> 2013; McElroy <b>et</b> <b>al.</b> 2013).|$|R
30|$|The {{production}} of lignolytic enzymes and its regulation has been intensively studied in various lignin degrading fungi (Bonnarme &Jeffries 1990;Hakala <b>et</b> <b>al.</b> 2006; Jiménez-Tobon <b>et</b> <b>al.</b> 2003;Kamitsuji <b>et</b> <b>al.</b> 2004;Lankinen <b>et</b> <b>al.</b> 2005; Martínez <b>et</b> <b>al.</b> 1996;Moilanen <b>et</b> <b>al.</b> 1996;Nuske <b>et</b> <b>al.</b> 2002; Perie &Gold 1991;Palma <b>et</b> <b>al.</b> 2000;Petruccioli <b>et</b> <b>al.</b> 2009;Schneegab <b>et</b> <b>al.</b> 1997; Swamy &Ramsay 1999;Steffen <b>et</b> <b>al.</b> 2002;Susla <b>et</b> <b>al.</b> 2008;Silva <b>et</b> <b>al.</b> 2008;Sklenar <b>et</b> <b>al.</b> 2010;Singh <b>et</b> <b>al.</b> 2011; Taboada-Puig <b>et</b> <b>al.</b> 2011;Vares <b>et</b> <b>al.</b> 1995;Wang <b>et</b> <b>al.</b> 2001;Wang <b>et</b> <b>al.</b> 2008) and novel bacterial strains (Bharagava <b>et</b> <b>al.</b> 2009; Mishra &Thakur 2010;Yadav <b>et</b> <b>al.</b> 2011). Recombinant production {{has been studied}} in filamentous fungi (Conesa <b>et</b> <b>al.</b> 2000;Irie <b>et</b> <b>al.</b> 2001;Li <b>et</b> <b>al.</b> 2001;Mayfield <b>et</b> <b>al.</b> 1994;Stewart <b>et</b> <b>al.</b> 1996), yeasts (Jiang <b>et</b> <b>al.</b> 2008 a), bacterial (Whitwam &Tien 1996) and insect (Johnson <b>et</b> <b>al.</b> 1992; Pease <b>et</b> <b>al.</b> 1991) hosts with successful production but modest yields of active enzyme. MnP from P. chrysosporium has {{been the target of}} most recombinant studies, which however suffer from unsuccessful posttranslational protein modification and the need for exogenous heme in high concentrations (Jiang <b>et</b> <b>al.</b> 2008 a).|$|R
30|$|Proteasome phosphorylations {{are seen}} in almost every {{large-scale}} phosphoproteomic dataset. More importantly, the proteasome is dynamically phosphorylated {{in a variety of}} physiological and pathological processes, including development and stem/progenitor cell differentiation (Brill <b>et</b> <b>al.,</b> 2009; Rigbolt <b>et</b> <b>al.,</b> 2011; Goswami <b>et</b> <b>al.,</b> 2012), cell cycle (Beausoleil <b>et</b> <b>al.,</b> 2006; Dephoure <b>et</b> <b>al.,</b> 2008; Nagano <b>et</b> <b>al.,</b> 2009; Olsen <b>et</b> <b>al.,</b> 2010; Kettenbach <b>et</b> <b>al.,</b> 2011; Guo <b>et</b> <b>al.,</b> 2016), DNA damage response (Matsuoka <b>et</b> <b>al.,</b> 2007; Stokes <b>et</b> <b>al.,</b> 2007), stress responses (Um <b>et</b> <b>al.,</b> 2010; Wang <b>et</b> <b>al.,</b> 2014), immune signaling (Bose <b>et</b> <b>al.,</b> 2001; Bose <b>et</b> <b>al.,</b> 2004; Mayya <b>et</b> <b>al.,</b> 2009; Weintz <b>et</b> <b>al.,</b> 2010; Wu <b>et</b> <b>al.,</b> 2012), metabolic changes (Bardag-Gorce <b>et</b> <b>al.,</b> 2004; Zhang <b>et</b> <b>al.,</b> 2007 b; Trost <b>et</b> <b>al.,</b> 2012), neuronal activity (Djakovic <b>et</b> <b>al.,</b> 2009; Bingol <b>et</b> <b>al.,</b> 2010; Djakovic <b>et</b> <b>al.,</b> 2012; Hamilton <b>et</b> <b>al.,</b> 2012; Jarome <b>et</b> <b>al.,</b> 2013; Jarome <b>et</b> <b>al.,</b> 2016; Li <b>et</b> <b>al.,</b> 2016), hormones and growth factor signaling (Kim <b>et</b> <b>al.,</b> 2009; Pan <b>et</b> <b>al.,</b> 2009; Lundby <b>et</b> <b>al.,</b> 2013; Williams <b>et</b> <b>al.,</b> 2016), and oncogenesis (Rush <b>et</b> <b>al.,</b> 2005; Rikova <b>et</b> <b>al.,</b> 2007; Guo <b>et</b> <b>al.,</b> 2008; Luo <b>et</b> <b>al.,</b> 2008; Choudhary <b>et</b> <b>al.,</b> 2009; Eang <b>et</b> <b>al.,</b> 2009; Iliuk <b>et</b> <b>al.,</b> 2010; Johnson <b>et</b> <b>al.,</b> 2012; Trost <b>et</b> <b>al.,</b> 2012; Yuan <b>et</b> <b>al.,</b> 2013). Although the functional roles of proteasome phosphorylation in these processes are largely uncharacterized, increasing evidence indicates that the 26 S proteasome is not a uniform and static complex acting passively as a “cellular trashcan”. Rather, the proteasome itself is fine-tuned by reversible phosphorylation in response to intra- and extra-cellular signals, which can be a prerequisite or feedback mechanism for a wide spectrum of cellular events that depend on proteasome function.|$|R
30|$|Hand, foot, {{and mouth}} disease is {{commonly}} caused by CA 16 and EV 71 with typical lesions on the hands, feet, mouth, buttock, elbows and knees (Chatproedprai <b>et</b> <b>al.</b> 2010; Hubiche <b>et</b> <b>al.</b> 2014). CA 6 {{emerged as a}} large scale outbreak in Thailand in 2012 and continued {{to be one of}} the major causes of HFMD worldwide (Wei <b>et</b> <b>al.</b> 2011; Flett <b>et</b> <b>al.</b> 2012; Fujimoto <b>et</b> <b>al.</b> 2012; Chung <b>et</b> <b>al.</b> 2013; Kaminska <b>et</b> <b>al.</b> 2013; Lott <b>et</b> <b>al.</b> 2013; Ben-Chetrit <b>et</b> <b>al.</b> 2014; Feder <b>et</b> <b>al.</b> 2014; Hubiche <b>et</b> <b>al.</b> 2014; Li <b>et</b> <b>al.</b> 2014; Sinclair <b>et</b> <b>al.</b> 2014). Unusual manifestations include widespread vesiculobullous and erosive lesions extending beyond the palms and soles (Wei <b>et</b> <b>al.</b> 2011; Chung <b>et</b> <b>al.</b> 2013; Kobayashi <b>et</b> <b>al.</b> 2013; Lott <b>et</b> <b>al.</b> 2013; Mathes <b>et</b> <b>al.</b> 2013; Feder <b>et</b> <b>al.</b> 2014; Hubiche <b>et</b> <b>al.</b> 2014) including dorsal sides of the hands and feet (Flett <b>et</b> <b>al.</b> 2012; Feder <b>et</b> <b>al.</b> 2014), calves and trunk (Feder <b>et</b> <b>al.</b> 2014), eczema herpeticum-like eruption termed “eczema coxsackium” (Mathes <b>et</b> <b>al.</b> 2013; Akkoyunlu <b>et</b> <b>al.</b> 2014; Sinclair <b>et</b> <b>al.</b> 2014), eruption similar to GCS (Mathes <b>et</b> <b>al.</b> 2013), petechiae or purpuric eruption (Mathes <b>et</b> <b>al.</b> 2013; Stewart <b>et</b> <b>al.</b> 2013), varicelliform (Yasui <b>et</b> <b>al.</b> 2013; Sinclair <b>et</b> <b>al.</b> 2014), delayed desquamation of palms and soles (Wei <b>et</b> <b>al.</b> 2011; Mathes <b>et</b> <b>al.</b> 2013), and onychomadesis (transient separation of proximal nail plate) during convalescence (Wei <b>et</b> <b>al.</b> 2011; Feder <b>et</b> <b>al.</b> 2014).|$|R
30|$|Although few {{previous}} {{reports have}} shown the characteristics of imaging findings of primary hepatic carcinoid tumors owing to their rarity, it has been thought, based on previous reports and our present cases, that the relatively characteristic imaging findings include cystic areas with hemorrhagic components (Takayasu <b>et</b> <b>al.</b> 1992; Abdel Wahab <b>et</b> <b>al.</b> 2006; Komatsuda <b>et</b> <b>al.</b> 2005; Ulusan <b>et</b> <b>al.</b> 2005; Touloumis <b>et</b> <b>al.</b> 2008; Imaoka <b>et</b> <b>al.</b> 1993; Fujino <b>et</b> <b>al.</b> 1998; Oh <b>et</b> <b>al.</b> 1998; Kehagias <b>et</b> <b>al.</b> 1999; Hirata <b>et</b> <b>al.</b> 2002; Aoki <b>et</b> <b>al.</b> 1992; Yeung <b>et</b> <b>al.</b> 2008; Shih <b>et</b> <b>al.</b> 2005) and early enhanced solid areas (Iwao <b>et</b> <b>al.</b> 2001; Lin <b>et</b> <b>al.</b> 2009; Takayasu <b>et</b> <b>al.</b> 1992; Abdel Wahab <b>et</b> <b>al.</b> 2006; Komatsuda <b>et</b> <b>al.</b> 2005; Ulusan <b>et</b> <b>al.</b> 2005; Touloumis <b>et</b> <b>al.</b> 2008; Iimuro <b>et</b> <b>al.</b> 2002; Gao J <b>et</b> <b>al.</b> 2011; Shah <b>et</b> <b>al.</b> 2007).|$|R
30|$|Many {{factors have}} been {{identified}} that seem to impact {{the mental health of}} populations affected by natural disasters, which contribute to the onset and severity of posttraumatic stress disorder (PTSD): female gender (Carr <b>et</b> <b>al.</b> 1995; Karanci and Rustemli 1995; Sharan <b>et</b> <b>al.</b> 1996; C. C. Chen <b>et</b> <b>al.</b> 2001; Basoglu <b>et</b> <b>al.</b> 2002; Livanou <b>et</b> <b>al.</b> 2002; Salcioglu <b>et</b> <b>al.</b> 2003; Kiliç and Ulusoy 2003; Chang <b>et</b> <b>al.</b> 2005; Montazeri <b>et</b> <b>al.</b> 2005; Sattler <b>et</b> <b>al.</b> 2006; Hansson <b>et</b> <b>al.</b> 1994; C. H. Chen <b>et</b> <b>al.</b> 2007; Kuwabara <b>et</b> <b>al.</b> 2008; Priebe <b>et</b> <b>al.</b> 2009; Steel <b>et</b> <b>al.</b> 2011; Ahmad <b>et</b> <b>al.</b> 2010; Dell'Osso <b>et</b> <b>al.</b> 2011 b; Zhang and Ho 2011), older (Carr <b>et</b> <b>al.</b> 1997; Salcioglu <b>et</b> <b>al.</b> 2003; Toyabe <b>et</b> <b>al.</b> 2006; C. H. Chen <b>et</b> <b>al.</b> 2007; Priebe <b>et</b> <b>al.</b> 2009; Zhang and Ho 2011) or younger age at trauma (Kato <b>et</b> <b>al.</b> 1996), lower education (Karanci and Rustemli 1995; Armenian <b>et</b> <b>al.</b> 2000; Basoglu <b>et</b> <b>al.</b> 2002; Kiliç and Ulusoy 2003; Montazeri <b>et</b> <b>al.</b> 2005; C. H. Chen <b>et</b> <b>al.</b> 2007; Priebe <b>et</b> <b>al.</b> 2009; Wang <b>et</b> <b>al.</b> 2009; Ahmad <b>et</b> <b>al.</b> 2010), epigenetic vulnerability (Broekman <b>et</b> <b>al.</b> 2007; Mehta and Binder 2012), previous psychiatric illness (Nolen-Hoeksema and Morrow 1991; Basoglu <b>et</b> <b>al.</b> 2002; Salcioglu <b>et</b> <b>al.</b> 2003), fear of death {{at the time of the}} disaster (Basoglu <b>et</b> <b>al.</b> 2002; Livanou <b>et</b> <b>al.</b> 2002; Bergiannaki <b>et</b> <b>al.</b> 2003; Salcioglu <b>et</b> <b>al.</b> 2003; Kiliç and Ulusoy 2003; Basoglu <b>et</b> <b>al.</b> 2004; Kuwabara <b>et</b> <b>al.</b> 2008), degree of exposure to the disaster (Goenjian <b>et</b> <b>al.</b> 1994; Carr <b>et</b> <b>al.</b> 1995; Armenian <b>et</b> <b>al.</b> 2000; Sattler <b>et</b> <b>al.</b> 2006; Wang <b>et</b> <b>al.</b> 2009; Zhang and Ho 2011), closer proximity to the epicenter of an earthquake (Ahmad <b>et</b> <b>al.</b> 2010), loss of loved ones (Basoglu <b>et</b> <b>al.</b> 2002; Livanou <b>et</b> <b>al.</b> 2002; Montazeri <b>et</b> <b>al.</b> 2005; Goenjian <b>et</b> <b>al.</b> 1994; Dell'Osso <b>et</b> <b>al.</b> 2011 a), property or resource loss (Freedy <b>et</b> <b>al.</b> 1994; Armenian <b>et</b> <b>al.</b> 2000; C. C. Chen <b>et</b> <b>al.</b> 2001; Bland <b>et</b> <b>al.</b> 2005; Sattler <b>et</b> <b>al.</b> 2006; C. H. Chen <b>et</b> <b>al.</b> 2007; Kuwabara <b>et</b> <b>al.</b> 2008; Sharan <b>et</b> <b>al.</b> 1996), having been trapped/injured under rubble and/or participation in rescue work (Basoglu <b>et</b> <b>al.</b> 2002; Salcioglu <b>et</b> <b>al.</b> 2003; Kuwabara <b>et</b> <b>al.</b> 2008; Ehring <b>et</b> <b>al.</b> 2011), greater number of traumatic experiences (Chang <b>et</b> <b>al.</b> 2005), relocation after a disaster (Najarian <b>et</b> <b>al.</b> 2001; Kiliç <b>et</b> <b>al.</b> 2006), less social support (Bland <b>et</b> <b>al.</b> 1997; Armenian <b>et</b> <b>al.</b> 2000; Sattler <b>et</b> <b>al.</b> 2006; Bland <b>et</b> <b>al.</b> 2005; Wang <b>et</b> <b>al.</b> 2009), and diminished individual coping (Olff <b>et</b> <b>al.</b> 2005). Within one month after exposure to an extreme traumatic stressor, a mental disorder, such as acute stress disorder (ASD) can manifest. ASD is characterized by the development of dissociative and re-experiencing of symptoms, marked avoidance, anxiety or increased arousal, and significant distress or functional impairment. A diagnosis of ASD seems to have predictive power for PTSD by reducing the number of symptoms required within the dissociative cluster criteria, identifying subsyndromal ASD (Bryant 2011).|$|R
30|$|PNPLA 3 polymorphisms {{have been}} {{reported}} to be associated with hepatic steatosis, inflammation, fibrosis, and carcinogenesis in NAFLD (Romeo <b>et</b> <b>al.</b> 2008; Rotman <b>et</b> <b>al.</b> 2010; Valenti <b>et</b> <b>al.</b> 2010; Sookoian and Pirola 2011; Burza <b>et</b> <b>al.</b> 2012; Kawaguchi <b>et</b> <b>al.</b> 2012; Kitamoto <b>et</b> <b>al.</b> 2013). PNPLA 3 polymorphisms have also been reported to be associated with hepatic steatosis, fibrosis, treatment response, and carcinogenesis in CHC (Valenti <b>et</b> <b>al.</b> 2011; Trepo <b>et</b> <b>al.</b> 2011; Cai <b>et</b> <b>al.</b> 2011; Valenti <b>et</b> <b>al.</b> 2012; Clark <b>et</b> <b>al.</b> 2012; Dunn <b>et</b> <b>al.</b> 2014; Ezzikouri <b>et</b> <b>al.</b> 2014; Moritou <b>et</b> <b>al.</b> 2013; Zampino <b>et</b> <b>al.</b> 2013; Trepo <b>et</b> <b>al.</b> 2014; Sato <b>et</b> <b>al.</b> 2013). However, several reports have not found an association of PNPLA 3 polymorphisms with fibrosis and carcinogenesis in CHC (Trepo <b>et</b> <b>al.</b> 2011; Nischalke <b>et</b> <b>al.</b> 2011; Rembeck <b>et</b> <b>al.</b> 2012; Miyashita <b>et</b> <b>al.</b> 2012; Takeuchi <b>et</b> <b>al.</b> 2013; Nakamura <b>et</b> <b>al.</b> 2013; Guyot <b>et</b> <b>al.</b> 2013).|$|R
30|$|Epidemiological {{studies on}} the {{association}} between physical activity and mammographic density have reported inconsistent results (Lopez <b>et</b> <b>al.</b> 2003; Monninkhof <b>et</b> <b>al.</b> 2007; Irwin <b>et</b> <b>al.</b> 2006; Masala <b>et</b> <b>al.</b> 2009; Siozon <b>et</b> <b>al.</b> 2006; Gram <b>et</b> <b>al.</b> 1999; Suijkerbuijk <b>et</b> <b>al.</b> 2006; Reeves <b>et</b> <b>al.</b> 2007; Samimi <b>et</b> <b>al.</b> 2008; Conroy <b>et</b> <b>al.</b> 2010; Peters <b>et</b> <b>al.</b> 2008). A few have reported a statistically significant inverse association between physical activity and mammographic density (Masala <b>et</b> <b>al.</b> 2009; Lopez <b>et</b> <b>al.</b> 2003; Irwin <b>et</b> <b>al.</b> 2006; Monninkhof <b>et</b> <b>al.</b> 2007). But most studies have {{found no evidence of}} an association (Peters <b>et</b> <b>al.</b> 2008; Suijkerbuijk <b>et</b> <b>al.</b> 2006; Siozon <b>et</b> <b>al.</b> 2006; Reeves <b>et</b> <b>al.</b> 2007; Samimi <b>et</b> <b>al.</b> 2008; Conroy <b>et</b> <b>al.</b> 2010; Gram <b>et</b> <b>al.</b> 1999). A number of these studies have reported a positive association between physical activity and mammographic density that attenuated after adjustments for BMI (Peters <b>et</b> <b>al.</b> 2008; Reeves <b>et</b> <b>al.</b> 2007).|$|R
30|$|Recently, the risk-benefit {{ratio of}} HT was reassessed for various ages and time {{intervals}} since menopause onset. The North American Menopause Society (NAMS) (NAMS 2012) proposed that {{duration of treatment}} {{should be limited to}} younger women up to the age of 50 to 59 years; beyond which, HT is associated with increased risks. Similar recommendations were issued by the International Menopause Society (IMS) in 2011 (Sturdee <b>et</b> <b>al.</b> 2011), which considered HT as a first-line therapy choice for climacteric symptoms. Finally, a global consensus on the use of HT was obtained by The American Society for Reproductive Medicine, The Asia Pacific Menopause Federation, The Endocrine Society, The European Menopause and Andropause Society, The International Menopause Society, The International Osteoporosis Foundation and The North American Menopause Society (de Villiers <b>et</b> <b>al.</b> 2013). They stated that HT “is the most effective treatment for vasomotor symptoms associated with menopause at any age, but benefits are more likely to outweigh risks for symptomatic women before the age of 60 years or within 10 years after menopause”. Although some HT restrictions have been withdrawn, there is still a considerable need for non-hormonal treatment alternatives, especially for elderly post-menopausal women or cancer patients of both genders. Therefore, this present work aimed to assess the risk-benefit ratio of various non-hormonal treatment options. Among them, four non-hormonal treatments appear to have significant evidence for a beneficial effect in treating vasomotor climacteric or androgen-ablation symptoms, although some studied the effects over a period shorter than 12 weeks: gabapentin/pregabalin (Loprinzi <b>et</b> <b>al.</b> 2002 a; Guttuso <b>et</b> <b>al.</b> 2003; Reddy <b>et</b> <b>al.</b> 2006; Loprinzi <b>et</b> <b>al.</b> 2007; Butt <b>et</b> <b>al.</b> 2008; Saadati <b>et</b> <b>al.</b> 2013; Agarwal <b>et</b> <b>al.</b> 2014; Pinkerton <b>et</b> <b>al.</b> 2014; Loprinzi <b>et</b> <b>al.</b> 2010; Pandya <b>et</b> <b>al.</b> 2004; Pandya <b>et</b> <b>al.</b> 2005; Bordeleau <b>et</b> <b>al.</b> 2010; Loprinzi <b>et</b> <b>al.</b> 2009; Moraska <b>et</b> <b>al.</b> 2010), SSRIs (Stearns <b>et</b> <b>al.</b> 2003; Stearns <b>et</b> <b>al.</b> 2005; Simon <b>et</b> <b>al.</b> 2013; Huang <b>et</b> <b>al.</b> 2013; Stearns <b>et</b> <b>al.</b> 2000; Gordon <b>et</b> <b>al.</b> 2006; Grady <b>et</b> <b>al.</b> 2007; Kerwin <b>et</b> <b>al.</b> 2007; Aedo <b>et</b> <b>al.</b> 2011; Kimmick <b>et</b> <b>al.</b> 2006; Wu <b>et</b> <b>al.</b> 2009; Suvanto-Luukkonen <b>et</b> <b>al.</b> 2005; Oktem <b>et</b> <b>al.</b> 2007; Loprinzi <b>et</b> <b>al.</b> 2002 b; Barton <b>et</b> <b>al.</b> 2010; Barton <b>et</b> <b>al.</b> 2003; Defronzo Dobkin <b>et</b> <b>al.</b> 2009; Freedman <b>et</b> <b>al.</b> 2011; Freeman <b>et</b> <b>al.</b> 2011; Carpenter <b>et</b> <b>al.</b> 2012; Ensrud <b>et</b> <b>al.</b> 2012), venlafaxine/desvenlafaxine (Evans <b>et</b> <b>al.</b> 2005; Loprinzi <b>et</b> <b>al.</b> 2006; Loprinzi <b>et</b> <b>al.</b> 1998; Carpenter <b>et</b> <b>al.</b> 2007; Quella <b>et</b> <b>al.</b> 1999; Loprinzi <b>et</b> <b>al.</b> 2000; Loibl <b>et</b> <b>al.</b> 2007; Buijs <b>et</b> <b>al.</b> 2009; Boekhout <b>et</b> <b>al.</b> 2011; Bordeleau <b>et</b> <b>al.</b> 2010; Vitolins <b>et</b> <b>al.</b> 2013; Speroff <b>et</b> <b>al.</b> 2008; Archer <b>et</b> <b>al.</b> 2009 a; Archer <b>et</b> <b>al.</b> 2009 b; Cheng <b>et</b> <b>al.</b> 2013; Bouchard <b>et</b> <b>al.</b> 2012; Pinkerton <b>et</b> <b>al.</b> 2013), and CREs (Drewe <b>et</b> <b>al.</b> 2013; Lopatka <b>et</b> <b>al.</b> 2007; Vermes <b>et</b> <b>al.</b> 2005; Liske <b>et</b> <b>al.</b> 2002; Frei-Kleiner <b>et</b> <b>al.</b> 2005; Schellenberg <b>et</b> <b>al.</b> 2012; Osmers <b>et</b> <b>al.</b> 2005; Ross 2012; Newton <b>et</b> <b>al.</b> 2006; Geller <b>et</b> <b>al.</b> 2009; Stoll 1987; Wuttke <b>et</b> <b>al.</b> 2003; Nappi <b>et</b> <b>al.</b> 2005; Bai <b>et</b> <b>al.</b> 2007; Uebelhack <b>et</b> <b>al.</b> 2006; Briese <b>et</b> <b>al.</b> 2007; Oktem <b>et</b> <b>al.</b> 2007; Huang <b>et</b> <b>al.</b> 2013; Pockaj <b>et</b> <b>al.</b> 2004; Jacobson <b>et</b> <b>al.</b> 2001; Pockaj <b>et</b> <b>al.</b> 2006; Hernández Munoz & Pluchino 2003; Rostock <b>et</b> <b>al.</b> 2011).|$|R
30|$|The culture {{isolated}} had {{efficiency of}} accumulating on the sheets. Similar biodegradation assay {{has been documented}} by Satlewal <b>et</b> <b>al.</b> Sah <b>et</b> <b>al.,</b> Kapri <b>et</b> <b>al.</b> 2010 a, Kapri <b>et</b> <b>al.</b> 2010 b, Negi <b>et</b> <b>al.,</b> Soni <b>et</b> <b>al.</b> (Negi <b>et</b> <b>al.</b> 2009; Negi <b>et</b> <b>al.</b> 2011; Sah <b>et</b> <b>al.</b> 2010 a; Satlewal <b>et</b> <b>al.</b> 2008; Soni <b>et</b> <b>al.</b> 2009; Soni <b>et</b> <b>al.</b> 2008).|$|R
30|$|Five {{articles}} reported OR (Abnet <b>et</b> <b>al.</b> 2008; Dar <b>et</b> <b>al.</b> 2013; Guha <b>et</b> <b>al.</b> 2007; Hiraki <b>et</b> <b>al.</b> 2008; Patel <b>et</b> <b>al.</b> 2013), two reported HR (Abnet <b>et</b> <b>al.</b> 2005 a; Michaud <b>et</b> <b>al.</b> 2008) and {{the other}} one reported RR (Abnet <b>et</b> <b>al.</b> 2001). One article was exclusive to men (Michaud <b>et</b> <b>al.</b> 2008), whereas the remaining studies included both men and women (Abnet <b>et</b> <b>al.</b> 2001, 2005 a, 2008; Dar <b>et</b> <b>al.</b> 2013; Guha <b>et</b> <b>al.</b> 2007; Hiraki <b>et</b> <b>al.</b> 2008; Patel <b>et</b> <b>al.</b> 2013). One article did not adjust for confounding factors (Patel <b>et</b> <b>al.</b> 2013), but the other seven articles adjusted to various risk factors for oesophageal cancer, such as age, sex and education (Abnet <b>et</b> <b>al.</b> 2001, 2005 a, 2008; Dar <b>et</b> <b>al.</b> 2013; Guha <b>et</b> <b>al.</b> 2007; Hiraki <b>et</b> <b>al.</b> 2008; Michaud <b>et</b> <b>al.</b> 2008). In addition, six articles controlled adjusted values, such as smoking and alcohol drinking (Abnet <b>et</b> <b>al.</b> 2001, 2008; Dar <b>et</b> <b>al.</b> 2013; Guha <b>et</b> <b>al.</b> 2007; Hiraki <b>et</b> <b>al.</b> 2008; Michaud <b>et</b> <b>al.</b> 2008).|$|R
